JP2015523364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523364A5 JP2015523364A5 JP2015520652A JP2015520652A JP2015523364A5 JP 2015523364 A5 JP2015523364 A5 JP 2015523364A5 JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015523364 A5 JP2015523364 A5 JP 2015523364A5
- Authority
- JP
- Japan
- Prior art keywords
- thiosulfate
- agent
- oxoprotective
- sepsis
- related condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 206010040047 Sepsis Diseases 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 235000019136 lipoic acid Nutrition 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 229960002663 thioctic acid Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 108010024636 Glutathione Proteins 0.000 claims 4
- 229960003180 glutathione Drugs 0.000 claims 4
- -1 sulfide compound Chemical class 0.000 claims 4
- 150000003464 sulfur compounds Chemical class 0.000 claims 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims 3
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 claims 3
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000002898 organic sulfur compounds Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- ZSILVJLXKHGNPL-UHFFFAOYSA-L S(=S)(=O)([O-])[O-].[Ag+2] Chemical compound S(=S)(=O)([O-])[O-].[Ag+2] ZSILVJLXKHGNPL-UHFFFAOYSA-L 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 241001061127 Thione Species 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- XYXNTHIYBIDHGM-UHFFFAOYSA-N ammonium thiosulfate Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=S XYXNTHIYBIDHGM-UHFFFAOYSA-N 0.000 claims 1
- FAYYUXPSKDFLEC-UHFFFAOYSA-L calcium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Ca+2].[O-]S([O-])(=O)=S FAYYUXPSKDFLEC-UHFFFAOYSA-L 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 claims 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical class [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 claims 1
- 229940083577 gold sodium thiosulfate Drugs 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- CQDMJJVHDPDPHO-UHFFFAOYSA-L magnesium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=S CQDMJJVHDPDPHO-UHFFFAOYSA-L 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 229940048910 thiosulfate Drugs 0.000 claims 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 claims 1
- KZNBHWLDPGWJMM-UHFFFAOYSA-J trisodium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane;gold(1+);dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[Au+].[O-]S([O-])(=O)=S.[O-]S([O-])(=O)=S KZNBHWLDPGWJMM-UHFFFAOYSA-J 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261667719P | 2012-07-03 | 2012-07-03 | |
| US61/667,719 | 2012-07-03 | ||
| US201261691787P | 2012-08-21 | 2012-08-21 | |
| US61/691,787 | 2012-08-21 | ||
| US201361748698P | 2013-01-03 | 2013-01-03 | |
| US61/748,698 | 2013-01-03 | ||
| PCT/US2013/049087 WO2014008273A2 (en) | 2012-07-03 | 2013-07-02 | Methods for treating, diagnosing and/or monitoring progression of oxo associated states |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523364A JP2015523364A (ja) | 2015-08-13 |
| JP2015523364A5 true JP2015523364A5 (cg-RX-API-DMAC7.html) | 2016-08-25 |
| JP6509112B2 JP6509112B2 (ja) | 2019-05-08 |
Family
ID=49882592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520652A Expired - Fee Related JP6509112B2 (ja) | 2012-07-03 | 2013-07-02 | オキソ関連状態の治療、診断および/またはその進行のモニタリングのための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150174160A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2866565A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6509112B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104582490A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013286876B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2915793A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014008273A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021522519A (ja) * | 2018-04-19 | 2021-08-30 | スティッキーセル ピーティーワイ リミテッドStickycell Pty Ltd | 感染症の技術分野における白血球補充 |
| US11406607B2 (en) | 2018-05-24 | 2022-08-09 | University Of Florida Research Foundation, Inc. | Compositions, methods of treatment, and containers including compositions |
| AU2023312830A1 (en) * | 2022-07-27 | 2025-02-20 | Redox Bioscience LLC | Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome |
| CA3262374A1 (en) | 2022-09-14 | 2024-03-21 | BiognoSYS AG | Methods to determine drug target residence time and to select best drug-target candidates |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9309387D0 (en) * | 1993-05-06 | 1993-06-16 | Wellcome Found | Nitric oxide scavengers |
| AU682894B2 (en) * | 1993-10-28 | 1997-10-23 | Institut National De La Recherche Agronomique | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man |
| US5990153A (en) * | 1997-05-05 | 1999-11-23 | Wood; John G. | Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury |
| US6712802B1 (en) * | 1997-11-04 | 2004-03-30 | Charles B. Cairns | Metabolic therapy directed at electron transport |
| EP1063228B1 (en) * | 1998-03-09 | 2005-01-19 | Takeda Pharmaceutical Company Limited | Cycloalkene derivatives, process for producing the same, and use |
| US20030190368A1 (en) * | 1998-03-11 | 2003-10-09 | Roland Stoughton | Methods of diagnosis and triage using cell activation measures |
| FR2791571B1 (fr) * | 1999-04-02 | 2002-10-04 | Sod Conseils Rech Applic | Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s) |
| PL213982B1 (pl) * | 2001-07-27 | 2013-05-31 | Nutricia Nv | Zastosowanie fosfolipidów, triglicerydów i cholesterolu oraz kompozycja do podawania dojelitowego |
| EP1302115A1 (fr) * | 2001-10-16 | 2003-04-16 | Societe Des Produits Nestle S.A. | Utilisation de cystathionine |
| DE10151764A1 (de) * | 2001-10-19 | 2003-05-08 | Basf Ag | Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln |
| CA2487866A1 (en) * | 2002-06-07 | 2003-12-18 | Cortical Pty Ltd | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| US20030235571A1 (en) * | 2002-06-19 | 2003-12-25 | Gabriel Gojon-Romanillos | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| WO2008156671A2 (en) * | 2007-06-13 | 2008-12-24 | Jay Pravda | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| US20100112088A1 (en) * | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
| AU2004308966A1 (en) * | 2003-12-23 | 2005-07-14 | Musc Foundaton For Research Development | Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
| FR2894482A1 (fr) * | 2005-12-14 | 2007-06-15 | Galderma Sa | Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema |
| US9383348B2 (en) * | 2008-06-21 | 2016-07-05 | John E. Repine | Compositions and methods for treating lung disorders |
| CN102781461A (zh) * | 2009-12-28 | 2012-11-14 | N.V.佩里科恩有限责任公司 | 局部用酰基谷胱甘肽制剂 |
-
2013
- 2013-07-02 CA CA2915793A patent/CA2915793A1/en not_active Abandoned
- 2013-07-02 EP EP13813630.4A patent/EP2866565A4/en not_active Withdrawn
- 2013-07-02 AU AU2013286876A patent/AU2013286876B2/en not_active Ceased
- 2013-07-02 CN CN201380043850.3A patent/CN104582490A/zh active Pending
- 2013-07-02 US US14/412,099 patent/US20150174160A1/en not_active Abandoned
- 2013-07-02 JP JP2015520652A patent/JP6509112B2/ja not_active Expired - Fee Related
- 2013-07-02 WO PCT/US2013/049087 patent/WO2014008273A2/en not_active Ceased
-
2017
- 2017-07-20 AU AU2017206229A patent/AU2017206229A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bevc et al. | Measurement of breath ammonia for detection of patients with chronic kidney disease | |
| Ren et al. | Dynamic change of hydrogen sulfide during global cerebral ischemia–reperfusion and its effect in rats | |
| JP2015523364A5 (cg-RX-API-DMAC7.html) | ||
| BR112019004075A2 (pt) | métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit. | |
| HRP20120743T1 (hr) | Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja | |
| MX2009013683A (es) | Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo. | |
| ATE537450T1 (de) | Igfbp2-biomarker | |
| DE602006021768D1 (de) | Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands | |
| JP2016118568A5 (cg-RX-API-DMAC7.html) | ||
| Chan et al. | Pathophysiological roles and clinical importance of biomarkers in acute coronary syndrome | |
| JP2013100285A5 (cg-RX-API-DMAC7.html) | ||
| FR2959414B1 (fr) | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire | |
| Kodavanti et al. | Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention | |
| MX2024005426A (es) | Derivados de 4h-imidazo[1,5-b]pirazol para diagnostico. | |
| WO2016163727A3 (ko) | 황화수소 검출용 방사성 프로브 | |
| Myszka et al. | Sodium hydrosulfide moderately alleviates the hallmark symptoms of Duchenne muscular dystrophy in mdx mice | |
| Kitzberger et al. | Severity of organ failure is an independent predictor of intracranial hypertension in acute liver failure | |
| WO2023215880A3 (en) | Compositions and methods for gys1 inhibition | |
| EP3851127A4 (en) | Composition for detecting hydrogen sulfide or measuring hydrogen sulfide concentration and composition comprising same as effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer | |
| JP2012524884A5 (cg-RX-API-DMAC7.html) | ||
| KR102219895B9 (ko) | 쯔쯔가무시병 진단용 조성물 및 이를 포함하는 키트 | |
| Golanski et al. | Revival of PFA-100–how far is it useful for the monitoring of ADP receptor antagonists? | |
| RU2011144028A (ru) | Эффекты пероральной композиции против потери костной массы и потери прикрепления | |
| MX348303B (es) | Métodos y composiciones para la evaluación de lesión renal utilizando ácido hialurónico. | |
| EP2405275A4 (en) | STABILIZER FOR MANAGEMENT TEST, MANAGEMENT TEST WITH STABILITY AND MEASUREMENT KIT WITH MANAGEMENT TEST |